Bioxent

BioXent is a South Korean biotechnology company specializing in the discovery and development of novel small molecule therapeutics, with a core focus on oncology and metabolic diseases. The company leverages its expertise in deubiquitinating enzymes (DUBs) and targeted protein degradation to address high-value medical targets. Its lead candidate, BX-101, is a highly selective inhibitor of Ubiquitin-specific protease 7 (USP7), designed to treat various solid tumors by modulating the tumor microenvironment. Beyond oncology, BioXent is advancing a pipeline of programs for non-alcoholic steatohepatitis (NASH) and fibrotic diseases. Founded in 2020, the company is backed by prominent venture capital firms and aims to deliver precision medicines to patients worldwide.